Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial by Rha, Sun Young, Prof, Oh, Do-Youn, MD, Yañez, Patricio, MD, Bai, Yuxian, MD, Ryu, Min-Hee, MD, Lee, Jeeyun, MD, Rivera, Fernando, MD, Alves, Gustavo Vasconcelos, MD, Garrido, Marcelo, MD, Shiu, Kai-Keen, MD, Fernández, Manuel González, MD, Li, Jin, MD, Lowery, Maeve A, MD, Çil, Timuçin, MD, Cruz, Felipe Melo, PhD, Qin, Shukui, MD, Luo, Suxia, MD, Pan, Hongming, MD, Wainberg, Zev A, MD, Yin, Lina, PhD, Bordia, Sonal, MD, Bhagia, Pooja, MD, Wyrwicz, Lucjan S, MD

Get full text